https://www.selleckchem.com/CDK.html
74; ECSIPOT-2 HR 3.41; p 0.0001). In the second validation cohort, mOS was 25.2, 12.5, and 3.0months for ECSIPOT-0, ECSIPOT-1, and ECSIPOT-2, respectively (ECSIPOT-0 HR = 1; ECSIPOT-1 HR 2.33; ECSIPOT-2 HR 8.46; p 0.0001). In the third validation cohort, mOS was 11.8, 8.1, and 4.6months for ECSIPOT-0, ECSIPOT-1, and ECSIPOT-2, respectively (ECSIPOT-0 HR = 1; ECSIPOT-1 HR 1.47; ECSIPOT-2 HR 3.17; p 0.0001). Multivariate analysis in all cohorts confirmed the ECSIPOT index as an independent prognostic factor for OS. The easy assessment a
Like
Comment
Share
